Cara Therapeutics | CARA - Selling And Administration Expenses


Cara Therapeutics reported $2.19M in Selling and Administration Expenses for its fiscal quarter ending in September of 2025.





Selling And Administration Expenses Change Date
Acadia Pharmaceuticals USD 146.73M 21.82M Dec/2025
Alterity Therapeutics Limited AUD 1.45M 703.96K Dec/2025
Assertio Holdings USD 16.73M 1.66M Sep/2024
Cara Therapeutics USD 2.19M 2.45M Sep/2025
Cassava Sciences USD 6.66M 1.24M Dec/2025
Chugai Pharma JPY 36.93B 9.04B Dec/2025
Cipla INR 13.25B 101.8M Dec/2025
Clal Biotechnology ILS 3.31M 513K Dec/2022
Compugen USD 2.21M 120K Dec/2025
CSL USD 1.23B 498M Dec/2025
Grifols EUR 320.45M 12.65M Dec/2025
Halozyme Therapeutics USD 64.64M 27.11M Dec/2025
J&J USD 6.75B 831M Dec/2025
Neurocrine Biosciences USD 301.8M 10.2M Dec/2025
Pacira USD 91.87M 70K Dec/2025
Pfizer USD 4.08B 894M Dec/2025
RedHill Biopharma USD 4.48M 1.52M Mar/2024
Supernus Pharmaceuticals USD 122.39M 57.29M Dec/2025
Vanda Pharmaceuticals USD 39.28M 1.71M Dec/2024